Glycemic control

Allison J Hahr, Mark E Molitch*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Glycemic control is essential to delay or possibly prevent the development of diabetic nephropathy. There are multiple glucose-lowering medications now available to help attain goal glycemic control but only some of them can be used safely in chronic kidney disease and others can be used safely with dose reductions. An ideal target for therapy is a hemoglobin A1c of approximately 7 % to minimize microvascular complications. However, achieving an A1c of 7 % can be difficult; it requires vigilance on the part of the patient and physician and is accompanied by higher rates of hypoglycemia.

Original languageEnglish (US)
Title of host publicationDiabetes and Kidney Disease
PublisherSpringer New York
Pages205-214
Number of pages10
ISBN (Electronic)9781493907939
ISBN (Print)9781493907922
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Glycemic control'. Together they form a unique fingerprint.

  • Cite this

    Hahr, A. J., & Molitch, M. E. (2014). Glycemic control. In Diabetes and Kidney Disease (pp. 205-214). Springer New York. https://doi.org/10.1007/978-1-4939-0793-9_16